Weight loss pill set to rival injections after promising studies
Stay up to date with notifications from The Independent
Notifications can be managed in browser preferences.
New daily weight loss pill to rival injections
- A new daily Weight Loss pill, amycretin, developed by Novo Nordisk, has shown promising results in initial studies.
- In trials, patients receiving weekly amycretin injections lost an average of 24.3 percent of their body weight over 36 weeks.
- Patients taking daily amycretin tablets achieved an average weight loss of 13.1 percent over 12 weeks.
- Amycretin works by targeting GLP-1 and amylin receptors to help control blood sugar and appetite.
- Side effects, including nausea and vomiting, were reported as mostly mild to moderate and resolved by the end of treatment.